GSK pushes more data for shingles vaccine, but no filing yet
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's shingles vaccine continues to demonstrate strong efficacy in all ages in Phase III trials but the company doesn't plan to file the product just yet.
You may also be interested in...
GSK Files Blockbuster Hopeful Shingrix With FDA
The shingles vaccine is considered one of the products with the biggest commercial potential for GSK in the near-term.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.